AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Aurinia Pharmaceuticals Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$16.49−0.02 (-0.12%)

Close on Oct 19, 2026

Market cap: $2.20B
P/E (TTM): 7.2
Dividend yield: –

Aurinia Pharmaceuticals Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	283	235	176	134	46	50	0.32	0.46	0.42	0.17
Cost of Revenue	33	28	14	5.66	1.09	0	0	–	–	–
Gross Profit	250	207	161	128	45	50	0.32	–	–	–
Research & Development	33	21	50	45	51	50	53	41	34	15
Selling, General & Admin	–	–	195	196	174	97	22	–	–	–
General & Administrative	102	172	195	196	174	97	22	14	–	–
Advertising Expenses	–	–	15	16	15	10	–	–	–	–
Operating Expenses	178	240	267	–	–	154	91	56	47	25
Total Costs & Expenses	178	240	267	246	226	154	91	–	–	–
Operating Income	105	-4.69	-92	-111	-181	-104	-91	-55	-47	-25
Interest Expense	4.33	4.84	2.78	0	0	–	0.04	0	–	–
Interest & Investment Income	14	17	17	5.12	0.53	1.52	2.70	2.23	0.70	0.03
Merger & Restructuring Charges	1.65	23	0	0	–	–	–	–	–	–
Pretax Income	114	7.45	-77	-106	-180	-103	-88	-53	-71	–
Income Tax Expense	-173	1.70	0.55	1.83	0.76	-0.09	0.14	0.07	0	0
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	-124	-64	-71	-23
Net Income	287	5.75	-78	-108	-181	-103	-88	-53	–	–
EPS (Basic)(per share)	2.14	0.04	-0.54	-0.76	-1.40	-0.87	-0.95	-0.63	-0.92	-0.66
EPS (Diluted)(per share)	2.07	0.04	-0.54	-0.76	-1.40	-0.87	-0.95	-0.63	-0.92	-0.66
Shares Outstanding (Basic, Weighted)(shares)	134	143	143	142	129	118	93	85	77	35
Shares Outstanding (Diluted, Weighted)(shares)	139	146	143	142	129	118	93	85	77	35
EBITDA	124	15	-80	-109	-178	-103	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 90.4%
Operating margin: 48.4%
Net margin: 100.8%
Return on equity, FY2025: 59.9%

Financial strength

Current ratio: 5.42
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 179.9%

Valuation

P/E ratio: 7.2
Price to sales: 7.07
Price to book: 3.58
Dividend yield: –